Cost-effectiveness analysis of tyrosine kinase inhibitors (erlotinib vs. gefitinib vs. afatinib) in non-small-cell lung cancer
F Nurhayati, Y Anggriani, E Syahruddin… - Journal of Applied …, 2021 - japsonline.com
Tyrosine kinase inhibitors (TKIs; eg, erlotinib, gefitinib, and afatinib) are the first-line therapy
for non-small-cell lung cancer (NSCLC) patients with epidermal growth factor receptor …
for non-small-cell lung cancer (NSCLC) patients with epidermal growth factor receptor …
Healthcare costs in patients with advanced non-small cell lung cancer and disease progression during targeted therapy: a real-world observational study
KE Skinner, AW Fernandes, MS Walker… - Journal of medical …, 2018 - Taylor & Francis
Aims: To assess healthcare costs during treatment with epidermal growth factor receptor
(EGFR) tyrosine kinase inhibitors (TKIs) and following disease progression in patients with …
(EGFR) tyrosine kinase inhibitors (TKIs) and following disease progression in patients with …
[HTML][HTML] LUX-Lung 8: a randomized, open-label, phase III trial of afatinib vs. erlotinib in patients with advanced squamous cell carcinoma of the lung as second-line …
Background Patients with advanced squamous cell carcinoma (SCC) of the lung have
limited treatment options. Although treatment with the EGFR tyrosine kinase inhibitor …
limited treatment options. Although treatment with the EGFR tyrosine kinase inhibitor …
An observational study to assess the molecular epidemiology and direct medical costs of epidermal growth factor receptor (EGFR) mutations in patients with advanced …
G Mountzios, S Lampaki, GA Koliou… - Lung Cancer: Targets …, 2021 - Taylor & Francis
Purpose Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the
preferred first-line option for patients with advanced, EGFR-mutant non-small cell lung …
preferred first-line option for patients with advanced, EGFR-mutant non-small cell lung …
[HTML][HTML] Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung: Final analysis of the randomised phase 3 …
Background LUX-Lung 8 was a randomised, controlled, phase 3 study comparing afatinib
and erlotinib as second-line treatment of patients with advanced squamous cell carcinoma …
and erlotinib as second-line treatment of patients with advanced squamous cell carcinoma …
Afatinib: a review in advanced non-small cell lung cancer
GM Keating - Targeted oncology, 2016 - Springer
Abstract Afatinib (Giotrif®, Gilotrif®) is an orally administered, irreversible inhibitor of the
ErbB family of tyrosine kinases. In the first-line treatment of patients with advanced lung …
ErbB family of tyrosine kinases. In the first-line treatment of patients with advanced lung …
The European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) applied to pivotal phase III randomized-controlled trials of tyrosine …
Introduction: To examine the magnitude of the clinical benefit from first-line tyrosine kinase
inhibitors (TKIs) advanced non-small cell lung cancer (NSCLC) with activating epidermal …
inhibitors (TKIs) advanced non-small cell lung cancer (NSCLC) with activating epidermal …
Survival outcomes of nonsmall cell lung cancer patients treated with Afatinib who are affected by early adverse events
Introduction. Afatinib is a first‐line treatment option for patients with an advanced nonsmall
cell lung cancer (NSCLC) expressing an epidermal growth factor receptor (EGFR) activating …
cell lung cancer (NSCLC) expressing an epidermal growth factor receptor (EGFR) activating …
Cost-Utility Of Afatinib And Gefitinib As First-Line Treatment For EGFR-Mutated Advanced Non-Small-Cell Lung Cancer
H Wang, C Zeng, X Li, Y Wang, X Li, W Ge - Future oncology, 2018 - Taylor & Francis
Aim: To evaluate the cost-utility of gefitinib and afatinib as first-line EGFR-mutated non-small-
cell lung cancer treatments from the Chinese healthcare system perspective. Materials & …
cell lung cancer treatments from the Chinese healthcare system perspective. Materials & …
[HTML][HTML] Afatinib in the treatment of squamous non-small cell lung cancer: a new frontier or an old mistake?
GL Russo, C Proto, MC Garassino - Translational lung cancer …, 2016 - ncbi.nlm.nih.gov
Lung squamous cell carcinoma represents approximately 20% of all non-small cell lung
cancer (NSCLC) and is associated with a very poor prognosis. In the randomized phase III …
cancer (NSCLC) and is associated with a very poor prognosis. In the randomized phase III …